Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of “Buy” from Analysts

Immunic, Inc. (NASDAQ:IMUX) has been given an average rating of “Buy” by the twelve brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $47.25.

Several analysts recently commented on the company. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Wall Street Zen raised Immunic from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a report on Friday, May 29th. Roth Capital reaffirmed a “buy” rating and set a $19.00 price target on shares of Immunic in a research report on Thursday, May 14th. Finally, Lifesci Capital upgraded Immunic to a “strong-buy” rating in a report on Monday, May 4th.

Hedge Funds Weigh In On Immunic

A number of large investors have recently added to or reduced their stakes in the company. CTC Alternative Strategies Ltd. acquired a new stake in shares of Immunic in the 1st quarter valued at about $27,000. Qube Research & Technologies Ltd acquired a new position in shares of Immunic during the third quarter worth about $29,000. ADAR1 Capital Management LLC acquired a new position in shares of Immunic during the first quarter worth about $33,000. Two Sigma Investments LP bought a new position in shares of Immunic during the third quarter worth about $52,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Immunic during the fourth quarter worth about $83,000. Institutional investors own 51.82% of the company’s stock.

Immunic Trading Up 0.4%

Shares of IMUX opened at $16.49 on Thursday. The stock has a market cap of $224.92 million, a P/E ratio of -3.76 and a beta of 1.41. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43. The stock’s 50-day moving average price is $14.98 and its two-hundred day moving average price is $12.67.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. As a group, equities analysts forecast that Immunic will post -3.88 EPS for the current year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.